Leading dementia charity launches three Drug Discovery Institutes
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
List view / Grid view
News
Two major scientific articles validate Effimune’s drug candidate
13 February 2015 | By Effimune
Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system...
Key bioelectronic medical patent for cancer treatment issued by the U.S. Patent & Trademark Office
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
9 February 2015 | By SensiQ Technologies/Inventiva
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation...
Nobel Laureate’s stem cell company Cell Therapy Limited sets new crowdfunding record raising £691,000 on Crowdcube
9 February 2015 | By Cell Therapy Ltd
UK biotech company Cell Therapy Limited has raised over £691,000 on Crowdcube to fund its breakthrough stem cell medicine, Heartcel™, which regenerates heart muscle to treat heart failure...
Genticel presents pipeline development at EUROGIN congress held in Seville, Spain
6 February 2015 | By Genticel
Genticel announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7...
Two major studies strengthen case for prostate cancer drug before chemotherapy
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
TxCell reports revenues for 2014 and updates on upcoming milestones
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
Rigontec GmbH Appoints Dr. Christian Schetter as CEO
5 February 2015 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the appointment of Dr. Christian Schetter as CEO...
Major study links two new genetic variants to breast cancer
5 February 2015 | By The Institute of Cancer Research
A worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer...
MRC Technology appoints General Counsel and Company Secretary
5 February 2015 | By MRC Technology
MRC Technology has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary...
Oncologic imaging innovation is enabling earlier detection of cancers
4 February 2015 | By Frost & Sullivan
Ongoing research aims to develop oncologic imaging technologies that diagnose cancer at the cellular level before the disease manifests, finds Frost & Sullivan...
Motif Bio announces intention to float on AIM
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464
2 February 2015 | By ABIVAX
ABIVAX today announced that enrollment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464...
